Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 3/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31373510 | 1.00 | CCR1 (0.47) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL28008057 | 0.81 | METAP2 (0.46) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL9709737 | 0.81 | PRMT5 (0.50) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL14649499 | 0.81 | KDM4E (0.47) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL9710251 | 0.77 | PRMT5 (0.46) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL28133510 | 0.77 | PRMT5 (0.42) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL26106623 | 0.77 | L3MBTL1 (0.45) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL26107478 | 0.77 | KDM4E (0.44) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL31347128 | 0.77 | KDM4E (0.44) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 | |
| SCHEMBL30612203 | 0.77 | L3MBTL1 (0.45) | CCR1CCR8L3MBTL1ALDH1A1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240083898-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2024-03-14 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3619210-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| WO-2018204176-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-11-08 | — | — | WO | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| EP-2061466-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | Xtl Biopharmaceuticals Ltd. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083898-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | CCR1 4225/4885CCR8 3282/4885L3MBTL1 2717/4885 |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | GTF3C4, HNF4A, TENT4A | CCR1 1820/4885CCR8 1897/4885L3MBTL1 3219/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | CCR1 4142/4885CCR8 3676/4885L3MBTL1 4316/4885 |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | CCR1 4615/4885CCR8 4376/4885L3MBTL1 2364/4885 |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | CCR1 4615/4885CCR8 4376/4885L3MBTL1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.